Loading…
X4 Pharmaceuticals, Inc. is projected to rise to $5.49 by 2027, a +24% move from its current price of $4.41. XFOR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.23 | $4.42 | $4.61 | +0.15% |
| Jul 14 | $4.17 | $4.42 | $4.69 | +0.31% |
| Jul 15 | $4.12 | $4.43 | $4.77 | +0.46% |
| Jul 16 | $4.08 | $4.44 | $4.83 | +0.62% |
| Jul 17 | $4.05 | $4.44 | $4.88 | +0.77% |
| Jul 18 | $4.02 | $4.45 | $4.93 | +0.93% |
| Jul 19 | $3.99 | $4.46 | $4.98 | +1.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.99 | $4.46 | $4.98 | +1.09% |
| Week 2 | $3.85 | $4.51 | $5.27 | +2.18% |
| Week 3 | $3.76 | $4.56 | $5.52 | +3.29% |
| Week 4 | $3.69 | $4.60 | $5.75 | +4.42% |
| Week 5 | $3.63 | $4.65 | $5.97 | +5.55% |
| Week 6 | $3.58 | $4.71 | $6.18 | +6.70% |
| Week 7 | $3.54 | $4.76 | $6.38 | +7.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
The company has license agreements with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
XFOR represents X4 Pharmaceuticals, Inc., a healthcare company traded under the symbol XFOR. The stock trades at a current price of $4.41 with a market cap of $415.95M, and it is ranked 3192. The 30-day technical picture shows bullish sentiment with a 14-day RSI of 60, and key moving averages: SMA50 at $4.07 and SMA200 at $3.82.
The price has defined support at $3.71 and resistance at $4.67, and the 30-day range spans from $3.34 to $5.82. The current price sits above both the SMA50 and the SMA200, suggesting a constructive near-term setup.
A major floor 25.1% below — a decisive break under it would weaken the trend.
The nearest floor, 15.9% below — buyers have tended to step in here.
The nearest ceiling, 5.9% above — a clean break opens room to run.
A major ceiling 18.4% above — clearing it would confirm fresh momentum.
Key XFOR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XFOR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.06 | Buy | $4.14 | Buy |
| MA 10 | $4.14 | Buy | $4.12 | Buy |
| MA 20 | $4.10 | Buy | $4.09 | Buy |
| MA 50 | $4.07 | Buy | $4.06 | Buy |
| MA 100 | $3.99 | Buy | $4.01 | Buy |
| MA 200 | $3.82 | Buy | $4.42 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.26 | Neutral |
| Stoch RSI (14) | 57.62 | Neutral |
| CCI (20) | 173.63 | Buy |
| Williams %R (14) | -35.62 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 10.25 | Buy |
| Bollinger %B (20,2) | 0.95 | Neutral |
| Stochastic %K (14) | 64.38 | Neutral |
| TRIX (15) | 0.07 | Buy |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 45.57 | Neutral |
| Momentum (10) | 0.42 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 4.02 | Buy |
| ADX (14) | 8.10 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is bullish with an RSI of 60 and a price comfortably above key moving averages. The SMA50 sits at $4.07 and the SMA200 at $3.82, with a near-term price floor (support) at $3.71 and a ceiling (resistance) of $4.67. Over the last 30 days, the price traded within $3.34 to $5.82, indicating a substantial trading range and liquidity.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.99 | $4.41 | $7.34 | 0% | Neutral | |
| $4.15 | $5.49 | $7.79 | +24% | Bullish | |
| $4.52 | $6.25 | $9.36 | +42% | Bullish | |
| $4.53 | $6.51 | $10.15 | +48% | Bullish | |
| $4.05 | $6.03 | $9.73 | +37% | Bullish | |
| $4.40 | $6.77 | $11.25 | +53% | Bullish | |
| $4.94 | $7.82 | $13.34 | +77% | Bullish | |
| $6.03 | $9.82 | $17.15 | +123% | Bullish | |
| $6.64 | $11.13 | $19.85 | +152% | Bullish | |
| $6.10 | $10.49 | $19.10 | +138% | Bullish | |
| $8.16 | $15.90 | $31.42 | +261% | Bullish | |
| $12.81 | $28.46 | $63.20 | +545% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.99 | $4.41 | $5.57 | +0.00% |
| August 2026 | $4.16 | $4.99 | $6.18 | +13.08% |
| September 2026 | $4.19 | $5.08 | $6.40 | +1.80% |
| October 2026 | $4.21 | $5.14 | $6.58 | +1.33% |
| November 2026 | $4.43 | $5.46 | $7.06 | +6.14% |
| December 2026 | $4.52 | $5.61 | $7.34 | +2.83% |
Click any year to see its month-by-month XFOR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
X4 Pharmaceuticals, Inc.'s 2026 outlook centres on $4.41, within a $2.99 to $7.34 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, XFOR could reach as high as $7.79, with a base case around $5.49 and support toward $4.15 — roughly +24% from $4.41. Buyers look set to stay in control over this stretch.
Expect XFOR to range from $4.52 to $9.36 through 2028. The $6.25 average target implies a +42% move from current prices. That is up +14% on the projected 2027 average. Momentum favours further upside here.
The XFOR price prediction for 2029 points to an average of $6.51 (low $4.53, high $10.15) — a potential gain of +48% on today's $4.41. Buyers look set to stay in control over this stretch.
In 2030, XFOR is projected to trade between $4.05 and $9.73, averaging $6.03 — a potential gain of +37% from today's $4.41. That is -7% versus the projected 2029 average. Momentum favours further upside here.
X4 Pharmaceuticals, Inc.'s 2031 outlook centres on $6.77, within a $4.40 to $11.25 range. That is up +12% on the projected 2030 average. That marks a +53% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, XFOR could reach as high as $13.34, with a base case around $7.82 and support toward $4.94 — roughly +77% from $4.41. Momentum favours further upside here.
Expect XFOR to range from $6.03 to $17.15 through 2033. The $9.82 average target implies a +123% move from current prices. That is up +26% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The XFOR price prediction for 2034 points to an average of $11.13 (low $6.64, high $19.85) — a potential gain of +152% on today's $4.41. Momentum favours further upside here.
In 2035, XFOR is projected to trade between $6.10 and $19.10, averaging $10.49 — a potential gain of +138% from today's $4.41. That is -6% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
X4 Pharmaceuticals, Inc.'s 2040 outlook centres on $15.90, within a $8.16 to $31.42 range. That is up +52% on the projected 2035 average. That marks a +261% change versus current levels. Momentum favours further upside here.
By 2050, XFOR could reach as high as $63.20, with a base case around $28.46 and support toward $12.81 — roughly +545% from $4.41. Buyers look set to stay in control over this stretch.
Investing $1,000 in XFOR today (≈ 226.75737 XFOR) could be worth
$6,454.21
+$5,454.21 (+545%) by 2050 · US Dollar
Based on the average projected XFOR price of $28.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XFORwould be worth at today's price.
$1,000 invested in XFOR on Jul 10, 2025 (≈ 636.942654 XFOR) would be worth
$2,808.92
+$1,808.92 (+180.9%) today · 2.81× · US Dollar
Based on a XFOR entry price of $1.57 vs. today's $4.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.13 | $1,067.8 | +6.8% |
| 1 month ago | $3.73 | $1,182.31 | +18.2% |
| 3 months ago | $4.1 | $1,075.61 | +7.6% |
| 6 months ago | $3.9 | $1,130.77 | +13.1% |
| 1 year ago | $1.57 | $2,808.92 | +180.9% |
| All time (5.0y) ago | $182.4 | $24.18 | -97.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XFOR forecast.
Our base-case forecast reaches $8.80 around 2033.
Implied market cap at $8.80: $830.01M
Forecasts indicate a multi-year upside with rising averages and sizable gains. In 2026 the avg price is $4.41 with a min of $2.99 and a max of $7.34, and ROI is 0 with a Neutral sentiment. By 2027 the avg rises to $5.48 with a max of $7.79 and ROI of 24.3% in a bullish context.
The path continues higher through 2028 ($6.26 avg, $9.38 max, 42% ROI) and 2029 ($6.51 avg, $10.15 max, 47.6% ROI). By 2030 the avg is $6.02, with a min $4.04 and a max $9.72 and a 36.5% ROI; 2031 shows $6.78 avg and $11.27 max (53.8% ROI), 2032 $7.82 avg and $13.34 max (77.4% ROI), 2033 $9.82 avg and $17.15 max (122.7% ROI), 2034 $11.14 avg and $19.88 max (152.7% ROI), and 2035 $10.48 avg and $19.07 max (137.6% ROI). The longer horizon shows 2040 at $15.94 avg with $31.50 max and 261.5% ROI, and 2050 at $28.42 avg with $63.11 max and 544.5% ROI, all in a bullish trajectory.
These are forecast estimates and not guarantees, with actual results subject to market and clinical development outcomes.
Tap a question to reveal the answer.
In 2030 the forecast shows an avg price of $6.02 with a min of $4.04 and a max of $9.72, and a ROI of 36.5% in a bullish context.
The forecast displays bullish sentiment in several years from 2027 onward, with average prices rising from $5.48 in 2027 to $28.42 in 2050 and ROI up to 544.5%. Note these are estimates, not guarantees.
The forecast shows a max of $10.15 in 2029, $17.15 in 2033, $31.50 in 2040, and $63.11 in 2050, so a price above $10 is possible in later years.
Current price is $4.41 and market cap is $415.95M.
The 30-day range is $3.34 to $5.82.
X4 Pharmaceuticals, Inc. Community Discussion
0Share your X4 Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.